Overview

This trial is active, not recruiting.

Conditions pancreatic cancer, adenocarcinoma
Treatment cytology specimen collection procedure
Sponsor Ohio State University Comprehensive Cancer Center
Start date November 2011
End date June 2015
Trial size 50 participants
Trial identifier NCT01646697, NCI-2012-00926, OSU-10110

Summary

This study is being done to investigate another way of evaluating margin status after pancreatectomy by using cytopathology (slide interpretation) as compared to the traditional method of surgical pathology

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Endpoint classification efficacy study
Intervention model single group assignment
Masking single blind (investigator)
Primary purpose diagnostic
Arm
(Experimental)
Patients undergo cytopathologic sample collection during pancreatic resection during which slides are gently pressed against the cut edge of the pancreas, the surgical bed, and along the superior mesenteric artery, and finally against the tumor itself.
cytology specimen collection procedure cytologic sampling
Undergo cytopathologic sample collection

Primary Outcomes

Measure
Local recurrence at the site of resection
time frame: up to 2 years

Eligibility Criteria

Male or female participants from 18 years up to 80 years old.

Inclusion Criteria: - patients undergoing pancreatic resection for a presumed, although not necessarily biopsy-proven pancreatic malignancy, - ages 18 years to 80 years old Exclusion Criteria: - Pregnant women

Additional Information

Official title Cytopathologic Margin Evaluation in Patients Undergoing Pancreatic Cancer Resection
Principal investigator Mark Bloomston
Description PRIMARY OBJECTIVES: I. To compare margin status on final pathology with margin status from cytopathologic evaluation. OUTLINE: Patients undergo cytopathologic sample collection during pancreatic resection during which slides are gently pressed against the cut edge of the pancreas, the surgical bed, and along the superior mesenteric artery, and finally against the tumor itself.
Trial information was received from ClinicalTrials.gov and was last updated in July 2015.
Information provided to ClinicalTrials.gov by Ohio State University Comprehensive Cancer Center.